Peptides for Focal Segmental Glomerulosclerosis (FSGS): Therapeutic Insights

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies are being explored for Focal Segmental Glomerulosclerosis (FSGS) to protect podocytes, reduce proteinuria, and mitigate fibrosis. These targeted interventions aim to preserve kidney function and slow the progression of this challenging glomerular disease.

{" ".join(current_paragraph)}